SLDB (Solid Biosciences) Beginning Cash Position: $298.45 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLDB Solid Biosciences Inc SLDB
34 GF Score
Price $9.07
! 2 Warning Signs
View Full Analysis

What is Solid Biosciences Beginning Cash Position?

Solid Biosciences SLDB +2.26% 34 Beginning Cash Position is $298.45 Mil as of Jun. 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Solid Biosciences's Beginning Cash Position for the quarter that ended in Jun. 2026 was $298.45 Mil.

Solid Biosciences's quarterly Beginning Cash Position declined from Dec. 2025 ($63.29 Mil) to Mar. 2026 ($61.89 Mil) but then increased from Mar. 2026 ($61.89 Mil) to Jun. 2026 ($298.45 Mil).

Solid Biosciences's annual Beginning Cash Position declined from Dec. 2023 ($157.22 Mil) to Dec. 2024 ($75.85 Mil) but then increased from Dec. 2024 ($75.85 Mil) to Dec. 2025 ($82.19 Mil).

Solid Biosciences Beginning Cash Position Related Terms

Solid Biosciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Solid Biosciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solid Biosciences Beginning Cash Position Chart

Solid Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 155.07 121.21 157.22 75.85 82.19

Solid Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 212.60 140.86 63.29 61.89 298.45
SLDB
34GF Score
Solid Biosciences Inc SLDB
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solid Biosciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $298.45 Mil mean?
Solid Biosciences (SLDB) has a Beginning Cash Position of $298.45 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Solid Biosciences and its competitors.
Is Solid Biosciences' Beginning Cash Position too high?
Solid Biosciences' current Beginning Cash Position is $298.45 Mil. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' Beginning Cash Position compare to MNPR and DSGN?
Solid Biosciences' Beginning Cash Position of $298.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Solid Biosciences and its competitors. Solid Biosciences's current Beginning Cash Position is $298.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current Beginning Cash Position of $298.45 Mil. The current Beginning Cash Position is $298.45 Mil. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current Beginning Cash Position is $298.45 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solid Biosciences Business Description

Address 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score

Get the complete analysis for SLDB

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.07
Price